## ICMJE DISCLOSURE FORM

Date: _	July 21 <sup>th</sup> ,	2022	
Your Na	ame: <u>Lan Ko</u>		
Manus	cript Title:	<b>Decoding Cancer and Herbal Renaissance</b>	
Manus	rint numbe	r (if known): ICM-22-12	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
	Time frame: Since the initial planning of the work					
1 1 1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Georgia Cancer Coalition Distinguished Cancer Scholar Award	This is a research grant award to the author at Augusta University during 2003-2009.			
		NIH grant to Dr. Nahid F. Mivechi (CA132640).	Collaborator Dr. Nahid F. Mivechi has spent her NIH grant on research materials in author's previous published studies that this review cites.			
		Time frame: past	: 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone				
3	Royalties or licenses	X None				

4	Consulting force	V Nana	
4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
c	educational events Payment for expert	V. None	
6	testimony	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	Issued	US9738936B2, US10443104B2, US9574240B2, CN102575285B
		Pending	US 16/545,161
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

## Please summarize the above conflict of interest in the following box:

The author received a grant award from the Georgia Cancer Coalition at Augusta University. The author's research materials were supported by NIH funding (CA132640) from a collaborator. The author is the inventor and owner of GT198 patents (US9738936B2, US10443104B2, CN102575285B, US 16/545,161) and CoAA patent (US9574240B2).

## Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.